Saturday, 15 February 2014

PubMed Update January 2014

10 papers this month, half of which relate to the United Kingdom. We continue to move forward.

Cropsey KL, Martin S, Clark CB, McCullumsmith CB, Lane PS, Hardy S, Hendricks PS, Redmond N.
J Opioid Manag. 2013 Nov-Dec;9(6):393-400.
Comments: Valuable survey of persons in the corrections system, under community supervision. Nearly half had used opioids and 40% of those had experienced an opioid overdose. Those who had overdosed were more likely to be white, female, and have higher educational attainment; they were also much more likely to have witnessed overdose, have seen someone die of overdose, and want training in overdose prevention and management.

Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.
Spine (Phila Pa 1976). 2014 Jan 29. [Epub ahead of print]
Comments: A review of studies evaluating short term use of opioids for chronic lower back pain. The studies evaluated all have major shortcomings so we’re left with little new information.

Adrish M, Duncalf R, Diaz-Fuentes G, Venkatram S.
Am J Case Rep. 2014 Jan 15;15:22-6
Comments: Being “down” with an overdose for a prolonged period can lead to complications such as rhabdomyolysis and nerve compression. This patient developed compartment syndrome, which is to say high pressure within the fascial compartment of the buttocks, requiring surgical intervention to spare her extremity.


Darke S, Farrell M.
Addiction. 2014 Jan 24. doi: 10.1111/add.12456. [Epub ahead of print]
Comments: If anyone is reading this, this article should lead to some discussion. It is hard to argue with the recent United States experience with broad availability of opioid analgesics and resultant four-fold increase in opioid overdose death rates. When OxyContin was the choice longacting agent, that was the offender, then providers shifted to prescribing methadone and that became the principal offender, then the offender switched to whichever longacting opioid became the dominant prescribed opioid in a given community. When those communities stop prescribing opioids, heroin tops the charts. While there is room for a lively debate and this paper does not help us solve the current US crisis, the central conclusion that merely making opioids widely available at a known dose and free of adulterants would not reduce overdose mortality on a community or national level seems valid. That said, it is conceivable that such availability reduces mortality among those already dependent on opioids – complicating any assessment.

Matheson C, Pflanz-Sinclair C, Aucott L, Wilson P, Watson R, Malloy S, Dickie E, McAuley A.
BMC Fam Pract. 2014 Jan 15;15(1):12.
Comments: A survey of general practitioners in Scotland demonstrating mixed knowledge and interest in overdose prevention. Many seemed to feel this was a specialist service rather than one that a generalist should provide. Those with more experience with drug use were generally more supportive.

Tait RJ, Lenton S.
Addiction. 2014 Feb;109(2):260-1.
Comments: A commentary on the OOKS and OOAS overdose scales produced in the UK.

Siegler A, Tuazon E, Bradley O'Brien D, Paone D.
Int J Drug Policy. 2013 Nov 8. pii: S0955-3959(13)00178-3. [Epub ahead of print]
Comments: I’ve been anxiously awaiting the papers coming out of New York. They’ve done a great job dedicating resources to tracking and attempting to reduce opioid overdose mortality. Please keep writing!

Bennett T, Holloway K, Bird SM.
Lancet. 2014 Jan 11;383(9912):124-5.
Comments: The title doesn’t really match the text, but this is a very nice brief analysis of non-fatal overdose events in Wales. 47% of opioid injectors had overdosed and 15% had overdosed in the preceding 12 months, with a median 2 overdose events during that period. Data such as these are invaluable in generating event-level estimates of opioid overdose occurrence and outcome.

Handley SA, Flanagan RJ.
Clin Toxicol (Phila). 2014 Jan 7. [Epub ahead of print]
Comments: Nice trend analysis of poisoning deaths in England and Wales demonstrating a fairly stable number of opioid related deaths over that period.

Stavseth LS, Kunøe N, Tanum L.
Tidsskr Nor Laegeforen. 2013 Nov 12;133(21):2231-2. Norwegian.
Comments: This appears to be a letter but that’s all I can tell!

Tuesday, 7 January 2014

PubMed Update November/December 2013

We close out 2013 with an impressive 25 papers in the final two months for a total count of 89 papers. Some interesting new approaches and perspectives, including a paper on the underappreciated role of adulterants, a couple of naltrexone papers, and lots of lay naloxone.

Caulkins JP, Everingham S, Kilmer B, Midgette G.
Curr Drug Abuse Rev. 2013 Dec 5. [Epub ahead of print]
Comments: Somewhat surprising data suggesting relatively separate markets for heroin, cocaine and methamphetamine.

Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L.
Drug Alcohol Rev. 2013 Dec 3. doi: 10.1111/dar.12095. [Epub ahead of print]
Comments: A systematic review concluding that the data for naltrexone implants for opioid dependence are insufficient for use outside of clinical trials.

Bohnert AS, Ilgen MA, Trafton JA, Kerns RD, Eisenberg A, Ganoczy D, Blow FC.
Clin J Pain. 2013 Nov 25. [Epub ahead of print]
Comments: What happened with opioid analgesic overdose deaths in the United States also happened in among veterans receiving care in the Veterans’ Administration.

Coffin P, Banta-Green C.
Ann Intern Med. 2013 Dec 10. doi: 10.7326/M13-2781. [Epub ahead of print] No abstract available.
Comments: Commentary on the reliance on opioids and minimizing the potential harms of stewardship efforts.

Eggertson L.
CMAJ. 2013 Nov 25. [Epub ahead of print] No abstract available.
Comments: This is really a news report in CMAJ about Canada’s BC naloxone program.

Straus MM, Ghitza UE, Tai B.
Subst Abuse Rehabil. 2013 Sep 2;2013(4). doi: 10.2147/SAR.S47463.
Comments: Good review of major initiatives to respond to increasing rates of opioid overdose mortality in the United States, including take-back programs, prescription drug monitoring programs, and naloxone distribution.

Mack KA; National Center for Injury Prevention and Control, CDC.
MMWR Surveill Summ. 2013 Nov 22;62 Suppl 3:161-3.
Comments: Review of drug-related deaths of the past decade.

Dertadian GC, Maher L.
Drug Alcohol Rev. 2013 Nov 21. doi: 10.1111/dar.12093. [Epub ahead of print]
Comments: Interesting case reports of transitions from oral prescription opioid consumption to illicit opioid injection. Unable to access for details.

Müller D, Desel H.
Dtsch Arztebl Int. 2013 Oct;110(41):690-9; quiz 700. doi: 10.3238/arztebl.2013.0690. Epub 2013 Oct 11.
Comments: Interesting analysis of all acute poisonings in the German poison control center over 26 years.

Origer A, Lopes da Costa S, Baumann M.
Eur Addict Res. 2013 Oct 31;20(2):87-93. [Epub ahead of print]
Comments: Interesting gender-based analysis suggesting that women may be at higher risk earlier in their drug use careers.

Baxter LE Sr, Campbell A, Deshields M, Levounis P, Martin JA, McNicholas L, Payte JT, Salsitz EA, Taylor T, Wilford BB.
J Addict Med. 2013 Nov-Dec;7(6):377-86. doi: 10.1097/01.ADM.0000435321.39251.d7.
Comments: Guidelines addressing methadone starting dose, dose escalation, and concomitant medications/drugs.

Favrod-Coune T, Baroudi M, Casillas A, Rieder JP, Gétaz L, Barro J, Gaspoz JM, Broers B, Wolff H.
Swiss Med Wkly. 2013 Nov 1;143:w13898. doi: 10.4414/smw.2013.13898.
Comments: No overdoses.

Håkansson A, Vedin A, Wallin C, Kral AH.
Lakartidningen. 2013 Jul 17-Aug 6;110(29-31):1340-2. Swedish. No abstract available.
Comments: Unable to access, but it would be fascinating to see the Swedish response to lay naloxone.

Shadnia S, Rahimi M, Hassanian-Moghaddam H, Soltaninejad K, Noroozi A.
Clin Toxicol (Phila). 2013 Sep-Oct;51(8):777-82. doi: 10.3109/15563650.2013.830732. Epub 2013 Aug 23.
Comments:

Brason FW 2nd, Roe C, Dasgupta N.
N C Med J. 2013 May-Jun;74(3):259-61. No abstract available.
Comments: Unable to access.

Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM.
Can J Public Health. 2013 Apr 18;104(3):e200-4.
Comments: Report from the first 8 months of naloxone trainings in Toronto!

Barbera N, Busardò FP, Indorato F, Romano G.
Forensic Sci Int. 2013 Apr 10;227(1-3):74-6. doi: 10.1016/j.forsciint.2012.08.041. Epub 2012 Sep 20.
Comments: Fascinating paper on the role of dextromethorphan, built upon evidence that dextromethorphan – an NMDA-recepter antagonist – decreases the expiratory phase of respiration and magnifies the respiratory depression induced by morphine. While adulterants may be more important than we’ve previously realized, how does one translate that to overdose prevention in the field?

Horvath M, Dunay G, Csonka R, Keller E.
Neuropsychopharmacol Hung. 2013 Dec;15(4):253-9.
Comments: Very exciting to see a review of drug overdose deaths in Budapest, Hungary. The number of deaths is remarkably low, with just 464 deaths in 18 years (299 opioid-related). Surprisingly 58% of the deaths were heroin alone, a finding the authors suggest means that use patterns are distinct in Budapest.

Cui N, Cao XB, Wang CH, Luo W, Pang L, Rou KM, Wu ZY.
Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Oct;34(10):961-3. Chinese.
Comments: Interesting analysis from China with the suggestion that adherence to methadone maintenance reduces overdose mortality.

Hewlett L, Wermeling DP.
J Opioid Manag. 2013 Sep-Oct;9(5):369-77. doi: 10.5055/jom.2013.0179.
Comments: Review of naloxone access laws in the United States. There was so much activity in 2013, that this article is already a bit out of date!

Cao X, Wu Z, Li L, Pang L, Rou K, Wang C, Luo W, Yin W, Li J, McGoogan JM; National Methadone Maintenance Treatment Program Working Group.
PLoS One. 2013 Dec 12;8(12):e82476. doi: 10.1371/journal.pone.0082476.
Comments: Overdose was the leading cause of death among methadone patients, four times more likely among those with HIV, and longer time in methadone treatment reduced overdose mortality risk.

Bonar EE, Ilgen MA, Walton M, Bohnert AS.
Am J Addict. 2014 Jan;23(1):41-7. doi: 10.1111/j.1521-0391.2013.12055.x. Epub 2013 Jun 14.
Comments: Analysis among substance users at a treatment center of pain, non-medical prescription opioid use, and overdose.

Cerdá M, Ransome Y, Keyes KM, Koenen KC, Tardiff K, Vlahov D, Galea S.
Am J Public Health. 2013 Dec;103(12):2252-60. doi: 10.2105/AJPH.2013.301347. Epub 2013 Oct 17.
Comments: This is a fascinating analysis that I’ve been waiting to see (AJPH does tend to take a while to publish!). However, what happened in NYC with opioid overdose may or may not be reflective of what happened in other areas of the country. NYC saw a clear increase in overdose on Staten Island, among those using prescription opioids, while heroin deaths were decreasing citywide. Staten Island then had an increase in heroin deaths as many transitioned to heroin and there were no services in place to limit the harms of heroin. In other areas there is less of a clear trend.

Okic M, Cnossen L, Crifasi JA, Long C, Mitchell EK.
J Anal Toxicol. 2013 Nov-Dec;37(9):629-35. doi: 10.1093/jat/bkt085.
Comments: Again demonstrating the limited utility of drug concentration in opioid overdose deaths.

Jones HE, Chisolm MS, Jansson LM, Terplan M.
Addiction. 2013 Feb;108(2):233-47. doi: 10.1111/j.1360-0443.2012.03811.x. Epub 2012 Apr 4. Review.
Comments: The research field of obstetrics is generally way behind the rest of medicine. Because we are so concerned over the health of pregnant women and the well-being of the embryos and fetuses they carry, we tend to rely on decades of experience and new approaches progress glacially. As the authors point out, given the numerous potential downsides of naltrexone for opioid dependence, we are not near the point of recommending this therapy for pregnant women at this time – or even researching it directly.


Wednesday, 27 November 2013

Narcana vs Death

An amazing mural conceived of and painted by Erin Ruch and Mikey Reger, artists with Mission Minicomix, in Clarion Alley, the Mission District of San Francisco.


Sunday, 10 November 2013

PubMed Update October 2013

A slight reprieve from the onslaught, only 6 articles this month – some of which are really interesting.

Wiegand T, Wax P, Smith E, Hart K, Brent J.
J Med Toxicol. 2013 Nov 1. [Epub ahead of print]
Comments: Fascinating TocIC Registry, including cases that were attended to by boarded medical toxicologists (so this would represent a tiny subset of the type of accidental drug overdoses we generally discuss on this site). I’m unable to access the full article.

De Cuyper A, Lambert M, Hantson P.
Acta Clin Belg. 2013 May-Jun;68(3):250-1. No abstract available.
Comments: Unable to access and no abstract available.

Meyer MA.
Neurol Int. 2013 Jul 22;5(3):e13. doi: 10.4081/ni.2013.e13.
Comments: There was a similar review we discussed in 2012. This is a devastating white matter neurologic disease that has been reported after severe opioid overdoses; tends to occur days to weeks after the event.

Cerdá M, Ransome Y, Keyes KM, Koenen KC, Tardiff K, Vlahov D, Galea S.
Am J Public Health. 2013 Dec;103(12):2252-60. doi: 10.2105/AJPH.2013.301347. Epub 2013 Oct 17.
Comments: Fascinating analysis of opioid analgesic overdose fatalities in New York City from 2000-2006, compared to heroin overdose deaths and non-overdose unintentional deaths. Opioid analgesic deaths basically fit in the middle in terms of neighborhood wealth and social structure, between heroin deaths (lower income, socially fragmented) and non-overdose deaths (higher income, less fragmented). This article is also the first academic publication I’ve seen that demonstrates the unique geographic nature of opioid analgesic overdose mortality in NYC – Staten Island is an epicenter, a location that was historically essentially exempt from heroin overdose death.

Okic M, Cnossen L, Crifasi JA, Long C, Mitchell EK.
J Anal Toxicol. 2013 Nov;37(9):629-35. doi: 10.1093/jat/bkt085.
Comments: Analysis of opioids in deaths in Kansas, including drug concentrations. The most notable finding is that there is a very wide range of concentrations in overdose deaths involving these agents, a result consistent with decades of toxicological literature suggesting that tolerance plays a big role on risk for overdose and subsequent death.

Williams AV, Marsden J, Strang J.
Addiction. 2013 Sep 17. doi: 10.1111/add.12360. [Epub ahead of print]

Comments: Authors randomized family members to receive just information versus a 60-minute training. They found that family members who went through the training scored higher on the standardized knowledge and attitude scales authors had previously published. Of note, naloxone was administered in witnessed overdose events for 3 out of 92 who just received information and 5 out of 95 who received the 60-minute training. This raises the very different question of what is sufficient for non-medical personnel to safely and effectively administer naloxone in the community? Information alone may be the answer to that question. While in-depth trainings are fantastic when available and accessible, requiring such activities can easily become an unnecessary obstacle to dissemination of the intervention … perhaps similar to historic requirements for extensive counseling and consent processes prior to HIV testing.